NEW YORK/SINGAPORE (Reuters) -Asia shares rose on Thursday, tracking gains on Wall Street following a see-saw session, while ...

US stock futures fell on Wednesday after disappointing earnings from Alphabet, while the dollar took a dive against the yen, which rallied sharply after Japanese wage data upped the chances of another ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

EUROPEAN shares ended Wednesday’s choppy session higher, as a rise in healthcare companies GSK and Novo Nordisk following ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...

Stocks closed higher Wednesday as shares of big tech companies pared earlier losses. The sector slid on the heels of ...

The Dow Jones Industrial Average rose 317.24 points, or 0.71%, to 44,873.28, the S&P 500 rose 23.60 points, or 0.39%, to ...

"We think the leaders of other countries don't really understand Trump's art of the deal," said Jay Hatfield, CEO and ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Wall Street struggled for direction and benchmark Treasury yields slid on Wednesday as disappointing earnings and mixed ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...